Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Entain sees 'strong' performance in many markets during Q1

(Sharecast News) - Entain reported an in line performance for its first quarter. In a trading update, boss Stella David said management was "particularly encouraged" by customer engagement in the US with its first quarter performance having been bolstered by "strong" performances in many of its markets.

Net Gaming Revenues, including its 50% stake in BetMGM, were ahead by 6% at constant currencies.

International NGR was ahead by 8%, including an "encouraging" return to "good" growth in Brazil.

NGR in Croatia and Poland continued to perform well, jumping by 130%.

David also expressed confidence in the sports-betting outfit`s ability to continue driving organic growth into 2025 and beyond.

"We look forward to building on this momentum as we focus on our strategic priorities of organic revenue growth, margin expansion and winning in the U.S.," she said.

"We remain confident that our continued focused execution will drive organic growth into 2025 and beyond."

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.